Considerations for Pharmacoepidemiological Studies of Drug–Cancer Associations
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
In this MiniReview, we provide general considerations for the planning and conduct of pharmacoepidemiological studies of associations between drug use and cancer development. We address data sources, study design, assessment of drug exposure, ascertainment of cancer outcomes, confounder adjustment and future perspectives. Aspects of data sources include assessment of complete history of drug use and data on dose and duration of drug use, allowing estimates of cumulative exposure. Outcome data from formal cancer registries are preferable, but cancer data from other sources, for example, patient or pathology registries, medical records or claims are also suitable. The two principal designs for observational studies evaluating drug–cancer associations are the cohort and case–control designs. A key challenge in studies of drug–cancer associations is the exposure assessment due to the typically long period of cancer development. We present methods to examine early and late effects of drug use on cancer development and discuss the need for employing ‘lag‐time’ in order to avoid reverse causation. We emphasize that a new‐user study design should always be considered. We also underline the need for ‘dose–response’ analyses, as drug–cancer associations are likely to be dose‐dependent. Generally, studies of drug–cancer associations should explore risk of site‐specific cancer, rather than cancer overall. Additional differentiation may also be crucial for organ‐specific cancer with various distinct histological subtypes (e.g., lung or ovary cancer). We also highlight the influence of confounding factors and discuss various methods to address confounding, while emphasizing that the choices of methods depend on the design and specific objectives of the individual study. In some studies, use of active comparator(s) may be preferable. Pharmacoepidemiological studies of drug–cancer associations are expected to evolve considerably in the coming years, due to the increasing availability of long‐term data on drug exposures and cancer outcomes, the increasing conduct of multinational studies, allowing studies of rare cancers and subtypes of cancer, and methodological improvements specifically addressing cancer and other long‐term outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Skin cancers after organ transplantation
Euvrard, S., Kanitakis, J., & Claudy, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022137 · Cited by 1,575
Spectrum of cancer risk among US solid organ transplant recipients
Engels, E. A., Pfeiffer, R. M., Fraumeni, J. F., Kasiske, B. L., Israni, A. K., Snyder, J. J., Wolfe, R. A., Goodrich, N. P., Bayakly, A. R., Clarke, C. A., et al. (2011) · JAMA · doi:10.1001/jama.2011.1592 · Cited by 1,524
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Rothwell, P. M., Price, J. F., Fowkes, F. G. R., Zanchetti, A., Roncaglioni, M. C., Tognoni, G., Lee, R., Belch, J. F., Wilson, M., Mehta, Z., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61720-0 · Cited by 839
Cook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739
Self-citationPer-Protocol Analyses of Pragmatic Trials
Hernán, M. A., & Robins, J. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmsm1605385 · Cited by 660
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists
Mansournia, M. A., Higgins, J. P. T., Sterne, J. A. C., & Hernán, M. A. (2017) · Epidemiology · doi:10.1097/ede.0000000000000564 · Cited by 285
Lochhead, P., Chan, A. T., Nishihara, R., Fuchs, C. S., Beck, A. H., Giovannucci, E., & Ogino, S. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.81 · Cited by 206
Murray, E. J., & Hernán, M. A. (2016) · Clinical Trials · doi:10.1177/1740774516634335 · Cited by 57
Garry, E. M., Buse, J. B., Lund, J. L., Pate, V., & Stürmer, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13049 · Cited by 25
Self-citation
Cited by
Langan, S. M., Schmidt, S. A., Wing, K., Ehrenstein, V., Nicholls, S. G., Filion, K. B., Klungel, O., Petersen, I., Sorensen, H. T., Dixon, W. G., et al. (2018) · BMJ · doi:10.1136/bmj.k3532 · Cited by 550
Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts
Thompson, C. A., & Stürmer, T. (2023) · Diabetes Care · doi:10.2337/dci22-0052 · Cited by 51
Self-citationUse of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Ueda, P., Wintzell, V., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Svanström, H., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05508-1 · Cited by 31
Metadata
- Authors
- Pottegård, A., Friis, S., Stürmer, T., Hallas, J., & Bahmanyar, S.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2018-01-15
- Volume
- 122
- Issue
- 5
- Pages
- 451-459
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W2778435052
- Cited by
- 101
- References
- 16
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.